Seroatlas · Human Serome Atlas

PTPRN2

Receptor-type tyrosine-protein phosphatase N2

Also known as: IA-2beta, ICAAR, KIAA0387, phogrin, PTPR2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q92932
Gene
PTPRN2
Ensembl
ENSG00000155093
Chromosome
7
Canonical length
1015 aa
Protein class
Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters
Subcellular location
Vesicles

OverviewNCBI Gene

This gene encodes a protein with sequence similarity to receptor-like protein tyrosine phosphatases. However, tyrosine phosphatase activity has not been experimentally validated for this protein. Studies of the rat ortholog suggest that the encoded protein may instead function as a phosphatidylinositol phosphatase with the ability to dephosphorylate phosphatidylinositol 3-phosphate and phosphatidylinositol 4,5-diphosphate, and this function may be involved in the regulation of insulin secretion. This protein has been identified as an autoantigen in insulin-dependent diabetes mellitus. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2015]

Canonical amino-acid sequenceUniProt

1015 residues, UniProt reviewed canonical sequence.

>Q92932|PTPRN2
     1  MGPPLPLLLL LLLLLPPRVL PAAPSSVPRG RQLPGRLGCL LEEGLCGASE ACVNDGVFGR
    61  CQKVPAMDFY RYEVSPVALQ RLRVALQKLS GTGFTWQDDY TQYVMDQELA DLPKTYLRRP
   121  EASSPARPSK HSVGSERRYS REGGAALANA LRRHLPFLEA LSQAPASDVL ARTHTAQDRP
   181  PAEGDDRFSE SILTYVAHTS ALTYPPGSRT QLREDLLPRT LGQLQPDELS PKVDSGVDRH
   241  HLMAALSAYA AQRPPAPPGE GSLEPQYLLR APSRMPRPLL APAAPQKWPS PLGDSEDPSS
   301  TGDGARIHTL LKDLQRQPAE VRGLSGLELD GMAELMAGLM QGVDHGVARG SPGRAALGES
   361  GEQADGPKAT LRGDSFPDDG VQDDDDRLYQ EVHRLSATLG GLLQDHGSRL LPGALPFARP
   421  LDMERKKSEH PESSLSSEEE TAGVENVKSQ TYSKDLLGQQ PHSEPGAAAF GELQNQMPGP
   481  SKEEQSLPAG AQEALSDGLQ LEVQPSEEEA RGYIVTDRDP LRPEEGRRLV EDVARLLQVP
   541  SSAFADVEVL GPAVTFKVSA NVQNVTTEDV EKATVDNKDK LEETSGLKIL QTGVGSKSKL
   601  KFLPPQAEQE DSTKFIALTL VSLACILGVL LASGLIYCLR HSSQHRLKEK LSGLGGDPGA
   661  DATAAYQELC RQRMATRPPD RPEGPHTSRI SSVSSQFSDG PIPSPSARSS ASSWSEEPVQ
   721  SNMDISTGHM ILSYMEDHLK NKNRLEKEWE ALCAYQAEPN SSFVAQREEN VPKNRSLAVL
   781  TYDHSRVLLK AENSHSHSDY INASPIMDHD PRNPAYIATQ GPLPATVADF WQMVWESGCV
   841  VIVMLTPLAE NGVRQCYHYW PDEGSNLYHI YEVNLVSEHI WCEDFLVRSF YLKNLQTNET
   901  RTVTQFHFLS WYDRGVPSSS RSLLDFRRKV NKCYRGRSCP IIVHCSDGAG RSGTYVLIDM
   961  VLNKMAKGAK EIDIAATLEH LRDQRPGMVQ TKEQFEFALT AVAEEVNAIL KALPQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against PTPRN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.48
Highest tissue expression
93 nTPM

Expression across tissuesHPA

Tissue

  • pancreas: 93 nTPM
  • cerebral cortex: 60 nTPM
  • basal ganglia: 57 nTPM
  • hypothalamus: 50 nTPM
  • amygdala: 44 nTPM
  • hippocampal formation: 42 nTPM

Single-cell type

  • gonadotrophs: 911 nCPM
  • lactotrophs: 836 nCPM
  • somatotrophs: 828 nCPM
  • brain inhibitory neurons: 788 nCPM
  • thyrotrophs: 733 nCPM
  • other brain neurons: 692 nCPM

Immune cell

  • neutrophil: 24 nTPM
  • basophil: 14 nTPM
  • T-reg: 5.3 nTPM
  • naive B-cell: 4.2 nTPM
  • memory B-cell: 3.5 nTPM
  • eosinophil: 2.8 nTPM

Brain region

  • cerebral cortex: 182 nTPM
  • hippocampal formation: 150 nTPM
  • basal ganglia: 139 nTPM
  • amygdala: 129 nTPM
  • hypothalamus: 128 nTPM
  • white matter: 119 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about PTPRN2.

Disease | ImmuneIEDB

Conditions an epitope on PTPRN2 was assayed in.

Disease | AutoantibodyPubMed

Conditions in which antibodies against PTPRN2 are reported. Each links to that disease's full target list.

ReferencesPubMed · IEDB

Publications for PTPRN2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.57
gnomAD pLI
0
gnomAD missense Z
0.06
DepMap mean gene effect
0.02
DepMap dependency class
none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of PTPRN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads PTPRN2 as an antibody target. Whether an autoantibody or antibody against PTPRN2 could matter depends on whether native PTPRN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

PTPRN2 is annotated at the cell surface, where native PTPRN2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Source-annotated serology context

The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.

  • This protein has been identified as an autoantigen in insulin-dependent diabetes mellitus.

Canonical record: https://seroatlas.com/gene/PTPRN2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...